Jiuyi Zheng

Jiuyi Zheng

Auto-generated profile, based on publicly available information

Jiuyi Zheng

Department of Hepatobiliary Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, People’s Republic of China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2022 in Experimental Cell Research
Verified
Journal Article
Closed access
FLFangting Liu
Fangting Liu
ZSZhehao Shi
Zhehao Shi
WBWenming Bao
Wenming Bao
JZJiuyi Zheng
Jiuyi Zheng
KCKaiyu Chen
Kaiyu Chen
XCXiaolei Chen
Xiaolei Chen

1 March 2023 in Journal of Hepatocellular Carcinoma
Verified
Journal Article
Open access
PDF file
MWMingxun Wang
Mingxun Wang
XYXinfei Yao
Xinfei Yao
ZBZhiyuan Bo
Zhiyuan Bo
JZJiuyi Zheng
Jiuyi Zheng
HYHaitao Yu
Haitao Yu
LWLijun Wu
Lijun Wu
Purpose: The current study aimed to evaluate the synergistic efficacy of lenvatinib and FOLFOX (infusional fluorouracil (FU), folinic acid, and oxaliplatin) in hepatocellular carcinoma (HCC) using patient-derived xenograft (PDX) and PDX-derived organotypic spheroid (XDOTS) models in vivo and in vitro. Methods: PDX and matched XDOTS models originating from three patients with HCC were established. All models were divided into four groups and treated with drugs alone or in combination. Tumor growth in the PDX models was measured and recorded, and angiogenesis and phosphorylation of the vascular endothelial growth factor receptor (VEGFR2), rearranged during transfection (RET), and extracellular signal-regulated kinase (ERK) were detected using immunohistochemistry and Western blot assays. The proliferative ability of XDOTS was evaluated through active staining and immunofluorescence staining, and the effect of the combined medication was evaluated using the Celltiter-Glo luminescent cell viability assay. Results: Three PDX models with genetic characteristics similar to those of the original tumors were successfully established. Combining lenvatinib with FOLFOX led to a higher tumor growth inhibition rate than individual therapies (P < 0.01). Immunohistochemical analysis demonstrated that the combined treatment significantly inhibited the proliferation and angiogenesis of PDX tissues (P < 0.05), and Western blot analysis showed that the combined treatment significantly inhibited the phosphorylation of VEGFR2, RET, and ERK compared with single-agent treatment. Additionally, all three matched XDOTS models were successfully cultured with satisfactory activity and proliferation, and the combined therapies led to better suppression of XDOTS growth compared with individual therapy (P < 0.05). Conclusion: Lenvatinib combined with FOLFOX had a synergistic antitumor effect in HCC PDX and XDOTS models by inhibiting the phosphorylation of VEGFR, RET, and ERK.

7 February 2023 in Asia-Pacific Journal of Clinical Oncology
Verified
Journal Article
Closed access
JZJiuyi Zheng
Jiuyi Zheng
BHBangjie He
Bangjie He
LDLiming Deng
Liming Deng
XZXuewen Zhu
Xuewen Zhu
RLRizhao Li
Rizhao Li
GCGang Chen
Gang Chen